| Literature DB >> 31467566 |
Selina Amankwah1,2, Francis Anto1.
Abstract
INTRODUCTION: Intermittent preventive treatment of malaria in pregnancy with sulfadoxine pyrimethamine (IPTp-SP) is effective in preventing the adverse consequences of malaria on birth outcomes.Entities:
Year: 2019 PMID: 31467566 PMCID: PMC6699305 DOI: 10.1155/2019/9278432
Source DB: PubMed Journal: J Trop Med ISSN: 1687-9686
Sociodemographic characteristics of study participants.
| Variable | Frequency | % |
|---|---|---|
|
| ||
| 18-24 | 73 | 19.1 |
| 25-31 | 179 | 46.9 |
| 32-38 | 107 | 28.0 |
| 39-45 | 23 | 6.0 |
|
| ||
| Single | 25 | 6.5 |
| Married | 297 | 77.8 |
| Cohabiting | 60 | 15.7 |
|
| ||
| No formal education | 60 | 15.7 |
| Basic | 198 | 52.0 |
| Secondary | 97 | 25.5 |
| Tertiary | 26 | 6.8 |
|
| ||
| Government/Private | 33 | 8.6 |
| Self employed | 275 | 72.0 |
| Unemployed | 74 | 19.4 |
|
| ||
| 0 | 41 | 10.7 |
| 1-2 | 243 | 63.6 |
| 3-4 | 87 | 22.8 |
| 5-7 | 11 | 2.9 |
Figure 1Time of first ANC visit and total number of visits made.
Figure 2Doses of SP taken by mothers who had delivered and those who had not yet delivered.
Figure 3Time of first ANC visit and number of SP doses received.
Sociodemographic characteristics of participants and IPTp-SP uptake.
|
|
|
|
| ||
|---|---|---|---|---|---|
| N = 382 | 0-2 doses | 3-4 doses | 5-6 doses | ||
|
| 0.855 | ||||
| 18-24 | 73 | 50.7 | 48.3 | 0.0 | |
| 25-31 | 179 | 54.7 | 43.6 | 1.7 | |
| 32-38 | 107 | 54.2 | 44.8 | 0.9 | |
| 39-45 | 23 | 47.8 | 52.2 | 0.0 | |
|
| 0.383 | ||||
| Single | 25 | 60.0 | 40.0 | 0.0 | |
| Married | 297 | 53.5 | 45.8 | 0.7 | |
| Cohabiting | 60 | 50.0 | 46.7 | 3.3 | |
|
| 0.786 | ||||
| No formal education | 60 | 51.7 | 48.3 | 0.0 | |
| Basic | 198 | 51.0 | 47.5 | 1.5 | |
| Secondary | 97 | 58.8 | 40.2 | 1.0 | |
| Tertiary | 26 | 57.7 | 42.3 | 0.0 | |
|
| 0.727 | ||||
| Government/Private | 33 | 48.5 | 51.5 | 0.0 | |
| Self employed | 275 | 51.5 | 45.1 | 1.5 | |
| Unemployed | 74 | 55.4 | 44.6 | 0.0 | |
|
| 0.097 | ||||
| 0 | 41 | 51.2 | 46.3 | 2.4 | |
| 1-2 | 243 | 51.4 | 48.1 | 0.4 | |
| 3-4 | 87 | 59.8 | 39.1 | 1.1 | |
| 5-7 | 11 | 54.5 | 36.4 | 9.1 | |
Implementation of DOT, drug side effects, and IPTp-SP uptake.
|
|
|
|
| ||
|---|---|---|---|---|---|
| N = 382 | 0-2 doses | 3-4 doses | 5-6 doses | ||
|
| 0.109 | ||||
| DOT observed | 288 | 39.8 | 34.6 | 1.0 | |
| DOT not observed | 87 | 11.8 | 11.0 | 0.0 | |
| NA | 7 | 1.8 | 0.0 | 0.0 | |
|
| 0.001 | ||||
| Information given | 231 | 27.5 | 31.9 | 1.0 | |
| No information given | 144 | 24.1 | 13.6 | 0.0 | |
| NA | 7 | 1.8 | 0.0 | 0.0 | |
|
| 0.133 | ||||
| Experienced side effects | 150 | 19.9 | 19.1 | 0.3 | |
| Side effect not experienced | 225 | 31.7 | 26.4 | 0.8 | |
| NA | 7 | 1.8 | 0.0 | 0.0 | |
|
| 0.132 | ||||
| Likes taking SP under DOT | 250 | 35.3 | 29.3 | 0.8 | |
| Does not like taking SP under DOT | 125 | 16.2 | 16.2 | 0.3 | |
| NA | 7 | 1.8 | 0.0 | 0.0 | |
|
| 0.172 | ||||
| Ever taken | 111 | 15.7 | 13.7 | 0.3 | |
| Never taken | 264 | 35.9 | 32.5 | 0.8 | |
| NA | 7 | 1.8 | 0.0 | 0.0 | |
|
| 0.122 | ||||
| Had malaria | 41 | 6.3 | 4.5 | ||
| Did not have malaria | 337 | 45.3 | 41.1 | 1.0 | |
| NA | 7 | 1.8 | 0.0 | 0.0 | |
Crude and adjusted associations between variables and uptake of IPTp-SP.
| Variable | Crude OR | 95%CI | Adjusted OR | 95%CI |
|---|---|---|---|---|
|
| ||||
| Information given | 0.46 | 0.30-0.70 | 2.16 | 1.34-3.47 |
| No information given | 1 | 1 | ||
|
| ||||
| 1st trimester | 1 | 1 | ||
| 2nd trimester | 1.71 | 1.13-2.59 | 1.18 | 0.73-1.90 |
| 3rd trimester | 6.20 | 2.04-18.89 | 2.18 | 0.65-7.31 |
|
| ||||
| ≥ 5 | 1 | 1 | ||
| < 5 | 0.17 | 0.11-0.2 | 0.19 | 0.12-0.31 |